
    
      This is a single-center, open label, non-controlled Phase IIa trial. Patients with first
      stage T.b. gambiense sleeping sickness will receive 100 mg of DB289 orally twice a day for 5
      days. Subjects meeting entry criteria will be enrolled at a single site.

      A total of 30 patients will be enrolled in this trial. Enrollment is planned to begin third
      quarter 2001 and be completed in 2-3 months.

      The study will be conducted at the Trypanosomiasis Reference Center, Viana (ICCT), Angola,
      and at the Trypanosomiasis Treatment Center in Maluku, Congo.
    
  